Stay updated with breaking news from Yates Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a
Phase 1 clinical trial advances with first subject dosed in the E.U. and IND accepted in the U.S. Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare
CEPI to provide up to USD4.3 million (AUD6.4 million) to Vaxxas to advance development of its high-density microarray patch for mRNA vaccines. Vaxxas' vaccine-delivery platform could improve access
Vaxxas to progress multiple vaccine programs in the clinic and ramp up manufacturing capabilities toward commercial scale.Equity funding to leverage non-dilutive financial support of more than US$67 million (A$100 million) which has been provided and committed under contracts with US and Australian government agenci...
CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced another key addition to its executive leadership team with the appointment of Doug Cubbin as Chief Financial Officer. Doug joins Vaxxas as the company...